脑栓通胶囊治疗缺血性卒中疗效与安全性的Meta分析
该Meta分析纳入13项RCT共1360例缺血性卒中患者,评估脑栓通胶囊(NSTC)的疗效与安全性。结果显示NSTC可显著提高总有效率(OR=3.04,95%CI[1.76,5.26],P<0.00001),改善神经功能(改良Barthel指数MD=8.15,95%CI[3.79,12.52],P=0.0005;功能独立性评定MD=29.61,95%CI[10.11,49.10],P=0.003;欧洲卒中量表MD=8.51,95%CI[7.00,10.01],P=0.03),升高血清脂联素(MD=0.66,95%CI[0.23,1.08],P=0.002),缩小动脉粥样硬化斑块面积(MD=-2.24,95%CI[-4.02,-0.46],P=0.01)及降低内中膜厚度(MD=-0.09,95%CI[-0.13,-0.05],P<0.0001)。
要点
- NSTC可提高缺血性卒中总有效率并改善神经功能。
- NSTC可升高血清脂联素并缩小动脉粥样硬化斑块面积。
- NSTC与常规治疗在Fugl-Meyer评分和Crouse评分上无显著差异。
核心结论
- 脑栓通胶囊治疗脑梗死显示出疗效,可提高总有效率、改善神经功能、升高血 adiponectin、减轻神经功能缺损并缩小动脉粥样硬化斑块面积。
研究设计与样本
- Meta分析纳入截至2018年9月前发表的13项随机对照试验,共1360例缺血性卒中患者。
- 两名研究者独立筛选文献并提取数据,采用Cochrane手册标准评估方法学质量,使用Review Manager 5.3软件分析。
主要发现
- NSTC显著提高总有效率(OR=3.04,95%CI[1.76,5.26],P<0.00001)。
- NSTC改善改良Barthel指数(MD=8.15,95%CI[3.79,12.52],P=0.0005)、功能独立性评定(MD=29.61,95%CI[10.11,49.10],P=0.003)和欧洲卒中量表评分(MD=8.51,95%CI[7.00,10.01],P=0.03)。
- NSTC升高血清脂联素水平(MD=0.66,95%CI[0.23,1.08],P=0.002)。
- NSTC缩小动脉粥样硬化斑块面积(MD=-2.24,95%CI[-4.02,-0.46],P=0.01)并降低内中膜厚度(MD=-0.09,95%CI[-0.13,-0.05],P<0.0001)。
- NSTC与常规治疗在Fugl-Meyer评定评分(MD=10.59,95%CI[-1.78,22.96],P=0.09)和Crouse评分(MD=-0.78,95%CI[-1.79,-0.22],P=0.13)上无显著差异。
临床怎么用
- 在缺血性卒中患者中,可考虑联合使用脑栓通胶囊以改善总有效率和神经功能。
- 脑栓通胶囊可能有助于升高脂联素和缩小动脉粥样硬化斑块,但需结合患者具体情况。
- 对Fugl-Meyer评分和Crouse评分,脑栓通胶囊未显示优于常规治疗,不应作为主要预期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not been statistically and systematically verified by any comprehensive pooled analysis. We therefore performed a meta-analysis to evaluate the efficacy and safety of NSTC in the treatment of IS. Methods: Randomized controlled trials (RCTs) of NSTC in the treatment of IS conducted before September 2018 were retrieved from five databases, according to specific inclusion and exclusion criteria. Two investigators independently reviewed the included studies and extracted relevant data. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook, and analyzed using Review Manager 5.3 software. Results: Thirteen RCTs comprising a total of 1,360 participants were included in this study. NSTC was shown to significantly improve the overall response rate (OR = 3.04, 95% CI [1.76, 5.26], P < 0.00001), and neurological function (NSTC increased Modified Barthel Index (MD = 8.15, 95% CI [3.79, 12.52], P = 0.0005), Functional Independence Measure (MD = 29.61, 95% CI [10.11, 49.10], P = 0.003) and European Stroke Scale scores (MD = 8.51, 95% CI [7.00, 10.01], P = 0.03). In addition, NSTC significantly increased serum adiponectin level (MD = 0.66, 95% CI [0.23, 1.08], P = 0.002). Moreover, NSTC reduced atherosclerotic plaque area (MD = -2.24, 95% CI [-4.02, -0.46], P = 0.01) and intima-media thickness (MD = -0.09, 95% CI [-0.13, -0.05], P < 0.0001). However, there was no significant difference between NSTC treatment and conventional therapy with respect to Fugl-Meyer Assessment score (MD = 10.59, 95% CI [-1.78, 22.96], P = 0.09) or Crouse score (MD = -0.78, 95% CI [-1.79, -0.22], P = 0.13). Conclusions: The results of this meta-analysis showed that NSTC exhibits efficacy in the treatment of cerebral infarction. NSTC can improve the overall response rate and neurological function, increase blood adiponectin, reduce neurological deficits, and decrease atherosclerotic plaque area.
引用
- Zhang H, Xing Y, Chang J, et al. Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis. Front Pharmacol. 2019. PMID: 31680944. doi:10.3389/fphar.2019.01133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。